Pfizer Biontech Vaccine Antibodies
- All
- News
-
Moderna's Shot Creates Twice As Many Antibodies As Pfizer, Study Shows
- Tuesday August 31, 2021
- World News | Jason Gale, Bloomberg
Moderna Inc.'s Covid vaccine generated more than double the antibodies of a similar shot made by Pfizer Inc. and BioNTech SE in research directly comparing immune responses to the inoculations.
- www.ndtv.com
-
Longer 8-Week Gap Between Pfizer Doses Boosts Antibodies, Study Finds
- Friday July 23, 2021
- World News | Janice Kew, Bloomberg
An interval of eight to 10 weeks between doses of the Covid-19 vaccine developed by Pfizer Inc. and BioNTech SE boosts the effectiveness of the two-shot regimen compared with a shorter interval, a U.K. study found.
- www.ndtv.com
-
South African Virus Variant Could Significantly Reduce Vaccine Protection: Pfizer
- Thursday February 18, 2021
- World News | Reuters
A laboratory study suggests that the South African variant of the coronavirus may reduce antibody protection from the Pfizer Inc/BioNTech SE vaccine by two-thirds, and it is not clear if the shot will be effective against the mutation, the companies said on Wednesday.
- www.ndtv.com
-
Moderna's Shot Creates Twice As Many Antibodies As Pfizer, Study Shows
- Tuesday August 31, 2021
- World News | Jason Gale, Bloomberg
Moderna Inc.'s Covid vaccine generated more than double the antibodies of a similar shot made by Pfizer Inc. and BioNTech SE in research directly comparing immune responses to the inoculations.
- www.ndtv.com
-
Longer 8-Week Gap Between Pfizer Doses Boosts Antibodies, Study Finds
- Friday July 23, 2021
- World News | Janice Kew, Bloomberg
An interval of eight to 10 weeks between doses of the Covid-19 vaccine developed by Pfizer Inc. and BioNTech SE boosts the effectiveness of the two-shot regimen compared with a shorter interval, a U.K. study found.
- www.ndtv.com
-
South African Virus Variant Could Significantly Reduce Vaccine Protection: Pfizer
- Thursday February 18, 2021
- World News | Reuters
A laboratory study suggests that the South African variant of the coronavirus may reduce antibody protection from the Pfizer Inc/BioNTech SE vaccine by two-thirds, and it is not clear if the shot will be effective against the mutation, the companies said on Wednesday.
- www.ndtv.com